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Genetic studies on PARK genes have identiﬁed dysfunction in proteasomal, lysosomal, and
mitochondrial enzymes as pathogenic for Parkinson’s disease (PD). We review the role of
these and similar enzymes in mediating innate immune signaling. In particular, we have
identiﬁed that a number of PARK gene products as well as other enzymes have roles in
innate immune signaling as well as DNA repair and regulation, ubiquitination, mitochondr-
ial functioning, and synaptic trafﬁcking. PD enzymatic dysfunction is likely to contribute to
inadequate innate immune responses to a variety of extra- and intra-cellular stimuli, with
a number of the innate immunity related enzymes found in the characteristic Lewy body
pathology of PD. The decrease in innate immunity in PD is associated with an increase
in markers of adaptive immunity, and recent GWAS studies have identiﬁed variants in
human leukocyte antigen region as associated with late-onset sporadic PD (Hamza et al.,
2010; Hill-Burns et al., 2011). Intriguing new data also suggest that peripheral immune
responses may be involved, giving some potential to alleviate such peripheral dysfunction
more directly in patients with PD. It is now important to identify the cell type speciﬁc
immune responses contributing to the initial changes that occur in PD, as well as to the
propagating immune responses important for the progression of PD pathology between
cells and within the brain. Overall, a complex interplay between different types of immunity
appear to be involved in the underlying pathology of PD.
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INTRODUCTION
Although Parkinson’s disease (PD) is the most common progres-
sive movement disorder in the elderly, there is still considerable
uncertainty about its etiology. Recent advances in genetics have
identiﬁed a number of PARKgenes in families with PD,which have
pointed to common underlying intrinsically driven intracellular
pathways (Corti et al., 2011). These include dysfunction of the pro-
teosome (McNaught et al., 2001), lysosome (Shin et al., 2005), and
mitochondria (Muqit et al., 2006). In particular, leucine repeat rich
kinase 2 (LRRK2, PARK8) and PTEN-induced kinase 1 (PINK1,
PARK6) are linked to familial dominant and recessive PD respec-
tively. PINK1 deletion causes aberrant expression of genes that
regulate innate immune responses (Akundi et al., 2011). LRRK2
expression is enriched in human immune cells and is a target gene
of IFN-γ (Gardet et al., 2010). Increased LRRK2 expression occurs
Abbreviations: CARD, caspase recruitment domain; CpG, polycytosine gua-
nine; ER, endoplasmic reticulum; HDAC, histone deacetylase; IKK, IκB kinase;
IRAK, interleukin-1 receptor-associated kinase; JNK, c-Jun N-terminal kinase; LPS,
lipopolysaccharides; LRRK2, leucine-rich repeat kinase 2;MAPK,mitogen-activated
protein kinase; MAPKK, MAPK kinase; MAVS, mitochondrial antiviral signaling;
Mda5, melanoma differentiation-associated gene 5; MPTP, 1-methyl-4-phenyl-1,
2,3,6-tetrahydropyridine; PAMPs, pathogen-associated molecular pattern; PARP,
poly (ADP-ribose) polymerase; PD, Parkinson’s disease; PINK1, PTEN-induced
putative kinase 1; PKR, Protein kinase RNA-activated; RIG-I, RNA helicases protein
retinoic acid-inducible gene I protein; TAK1, Transforming growth factor-beta-
activated kinase 1; TBK-1, TANK-binding kinase 1; TLR, Toll-like receptor; TRAF6,
tumor necrosis factor receptor-associated factor 6.
when an immune response is required (see below).Asmutations in
these proteins cause PD, this suggests that innate immunity may
play a more fundamental role in PD. How these systems inter-
act to cause the fundamental pathology of PD (intracellular Lewy
body inclusionsmade fromﬁbrilizedα-synuclein protein) to occur
within affected neurons needs to be addressed.
Despite considerable organelle dysfunction, neuronal death
occurs slowly, initially, and selectively targeting certain brainstem
regions with a predisposition for the substantia nigra (Fearnley
and Lees, 1991). Neuronal death does not occur in isolation, but
is accompanied by considerable neuroinﬂammation (Orr et al.,
2002;Wilms et al., 2003) and intrinsically driven glial cell changes
(Halliday and Stevens, 2011). These changes include the accumu-
lation of α-synuclein in glia, with many of the PARK gene proteins
also concentrating in glia in the human brain (LRRK2, PINK1,
DJ-1, parkin; Gandhi et al., 2006; Huang et al., 2008; Halliday
and Stevens, 2011; Song et al., 2011). As glia interact most closely
with the immune system, we will review how innate immunity is
involved in these processes.
The innate immune system is an immediate, non-speciﬁc, ﬁrst
line of defense against pathogen invasion, contrasting with the
delayed and targeted adaptive immune response (Stone et al.,
2009). The speciﬁc molecular structure of pathogens (pathogen-
associatedmolecular patterns or PAMPs), like lipopolysaccharides
(LPS) or the bacterial DNA motif polycytosine guanine (CpG),
are directly recognized by phagocytes, granulocytes, and natural
killer cells of the immune system (West et al., 2006). These PAMPs
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bind to Toll-like receptors (TLR) on cells, triggering a cascade of
signaling that results in pro-inﬂammatory cytokine release and
complement activation to clear the pathogen or the infected/dead
cell through macroautophagy (West et al., 2006).
Pathogens activate cells by binding to speciﬁc TLRs through
characteristic extracellular multiple leucine-rich repeats domains
of TLR (Nguyen et al., 2002). Theultimate inductionof interferons
and inﬂammatory cytokines bydifferent pathogens is ledby several
phosphorylation and subsequent ubiquitination events, with acti-
vation of TBK-1 and IKKε, JNK and p38 kinase, IKK, MAPK and
MAPKK, IRAK, and TAK1 [detailed in previous reviews (Kawai
and Akira, 2006; Seth et al., 2006)]. A major pathway is NF-κB
activation by its release from IκB allowing its nuclear translocation
and the subsequent activation of target genes to occur. IκB release
occurs following IκB phosphorylation and consequent degrada-
tion through the lysine 48 linked ubiquitin–proteasome system
(Silverman and Maniatis, 2001; Wu et al., 2006).
INNATE IMMUNITY AND PD
Classic PD is not considered an immune disease like multiple scle-
rosis, and can not be associated with common infectious agents.
However, Parkinsonian symptoms can occur after Epstein–Barr
virus (EBV) encephalitic infection in patients, with EBV DNA
detected in the brain (Espay and Henderson, 2011). This shows
that an immune activation in the brain can produce PD-like
symptoms, and a number of genetic studies suggest the immune
system is commonly involved. Genome-wide association studies
(GWAS) show that common variants in human leukocyte antigen
(HLA) region are associated with late-onset sporadic PD (Hamza
et al., 2010; Hill-Burns et al., 2011). The brains of individuals
with PD show upregulation of HLA-DR antigens and the pres-
ence of HLA-DR-immunopositive and highly reactive microglia
(McGeer et al., 1988). Microglia are the only cells in the substan-
tia nigra that express the initial recognition component of the
complement cascade, C1q (Carlsson et al., 2011). Finally, non-
steroidal anti-inﬂammatory drugs reduce PD risk (Wahner et al.,
2007; Steurer, 2011), further supporting some involvement of the
immune system in PD.
From a PARK gene perspective, it is of interest that both parkin
(PARK2) and LRRK2 (PARK8) are genes associated with leprosy
(Cardoso et al., 2011), which is a chronic infectious disease of
peripheral nerves. LRRK2 is also a risk gene for inﬂammatory
bowel disease (Van Limbergen et al., 2009; Torkvist et al., 2010;
Umeno et al., 2011), and there is much discussion about PD being
initiated from peripheral neurons within the gut (enteric nervous
system; Braak et al., 2003). In an animalmodel of ulcerative colitis,
there is an alteration of the blood–brain-barrier (BBB) permeabil-
ity that leads to more substantive cell loss to pathogen-induced
cell loss of the substantia nigra (Villaran et al., 2010). Interest-
ingly, treatment of the ulcerative colitis ameliorated cell loss in
the brain in this model (Villaran et al., 2010). This could sug-
gest a more direct link between immune defense mechanisms in
peripheral neurons and the later onset of PD. Deletions within
PINK1 (PARK6) or DJ-1 (PARK7) genes cause aberrant expres-
sion of genes involved in the p38 MAP kinase/NF-κB signaling
pathway causing changes in the regulation of the innate immune
response (Cornejo Castro et al., 2010; Akundi et al., 2011). This
suggests that many PARK genes also have signiﬁcant inﬂuence on
the immune system which may be important for the onset and/or
progression of PD.
A number of animal models of the neuronal loss in PD use
direct initiation of the innate immune system to model this aspect
of PD.Administration of LPS induces dramatic cell loss in primary
neuronal cultures and direct injection of LPS into the substantia
nigra produces progressive nigrostriatal degeneration and move-
ment abnormalities in animal models of PD (Liu, 2006; Dutta
et al., 2008). These LPS PD models trigger TLR4 mediated sig-
naling pathways (Carvey et al., 2003; Visintin et al., 2003). Even
intraperitoneal and in utero injections of LPS cause degeneration
of the nigrostriatal system (Ling et al., 2002; Perry, 2004), consis-
tent with peripheral effects causing PD-like neurodegeneration.
These innate immunity models of PD cause neurodegeneration
and microglial activation in a time and LPS dose dependent man-
ner (Liu, 2006; Dutta et al., 2008). Similar direct injections of
TLR3 into the substantia nigra produce nigrostriatal degeneration
(Deleidi et al., 2010). These studies show that strong stimulators
of the innate immune system and increased numbers of innate
immune receptors can produce signiﬁcant site-speciﬁc neurode-
generation, perhaps suggesting that the nigrostriatal system is
particularly vulnerable to immune activation.
Innate immune signaling also plays a role in the abnormal
deposition of α-synuclein. In α-synuclein overexpressing mod-
els, ablation of TLR4 augments the deposition of α-synculein due
to disruption of the ability of microglia to adequately phago-
cytose α-synuclein (Stefanova et al., 2011). This suggests that
certain aspects of innate immunity are required for initial pro-
tection from excessive extracellular α-synuclein. Whether these
mechanisms play a role in patients is more difﬁcult to determine.
Overall, these studies suggest that the innate immune system can
play both neuroprotective and neurotoxic roles depending on the
circumstances.
ADAPTIVE IMMUNITY AND PD
In contrast to the “non-speciﬁc” innate immune system, the adap-
tive immune response is cell mediated and highly specialized to
remove a speciﬁc antigen. It is mainly composed of two parts:
humoral immunity, which is mediated by B-lymphocytes, and
cell mediated immunity, which is mediated by T-lymphocytes.
The CNS was traditionally considered as an “immune privileged”
site due to its protection by the BBB, which prevents toxins and
infections from reaching the CNS. However, in PD the BBB is
disrupted due to activated microglia and monocytes in PD brain
(Stone et al., 2009). IgG, but not IgM, has been shown bound to
dopamine neurons in the substantia nigra of idiopathic and famil-
ial PD patients, but not in age-matched controls (Orr et al., 2005).
In addition, LRRK2, a causative gene for PD (see above), regulates
B2-lymphocyte function (Kubo et al., 2010). This suggests that
adaptive immunity may also be involved in the progression of PD
(Figure 1).
Apart from B-lymphocyte involvement in PD, both CD4+and
CD8+ T-lymphocytes have been found in the SN of PD patients,
and CD4+ T-lymphocytes are responsible for the T-cell-mediated
immunopathology (Brochard et al., 2009). The expression of
CD95 ligand (Fas) has been shown to be important for the capacity
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FIGURE 1 | Innate and adaptive immunity in PD. Innate and adaptive
immunity are both thought to affect the cellular response to PD. Both
produce cytokines facilitating microglial activation. Innate immune signaling
is initiated by PAMP binding. Innate immunity inﬂuences cell functions
through different organelles, such as the nucleus to affect DNA, the
mitochondria and proteasome, and through impacting on synaptic
trafﬁcking. Adaptive immunity is a subsequent response. Antigen speciﬁc
adaptive immune processes occur as immune cells survey the brain. In
response to stimuli, B cells secrete IgG and CD4T cells are activated
impacting on selective neuronal degeneration.
of T-lymphocytes to induce neuronal death (Brochard et al., 2009).
T-lymphocyte cells and T cell receptor (TCR) associated CD3, a
polypeptide complex comprised of four distinct chains (CD3γ,
CD3δ, CD3ε, and CD3ζ), are found in the PD characteristic Lewy
body lesions (Castellani et al., 2011), providing another direct link
between cell mediated immunity and PD pathology (Figure 1).
Through activation of both the adaptive and innate immune
systems, cytokines are induced and secreted. Circulating IL-12
and IL-10 are signiﬁcantly elevated in PD patients compared
with controls (Rentzos et al., 2009) and our data show that the
protein levels of IL-10 and GM-CSF are elevated in the cortex
of patients with PD (unpublished data). Intercellular adhesion
molecule-1 (ICAM-1)-positive glia are increased in the substantia
nigra of PD brains (Miklossy et al., 2006). Further analysis of these
immune responses in the brains of patients with PD may provide
more speciﬁc cytokine targets for modifying detrimental immune
responses in PD.
INNATE IMMUNITY AND DNA REPAIR AND REGULATION IN PD
The presence of genomic DNA single and double-strand breaks
is very common in PD affected brain regions (Hegde et al.,
2006). At early stages of DNA damage, DNA sensing molecules
(such as PARP and ATM) activate and cause a signaling cas-
cade for repair (Herceg and Wang, 2001). Histone deacetylases
(HDAC) are important suppressors of gene transcription, but also
deacetylates the p62 subunit of NF-κB increasing its binding to
IκB and suppressing innate immunity and interferon-stimulated
transcription (Babic et al., 2004; Into et al., 2010). HDACs have
been localized to Lewy bodies in patients with PD (Takahashi-
Fujigasaki and Fujigasaki, 2006), indicating that they are involved
in PD pathogenesis. Inhibiting HDAC alleviates dopamine deple-
tion in models of PD (Outeiro et al., 2007) and is protective by
enhancing α-synuclein expression in neurons (Nusinzon andHor-
vath, 2003; Leng and Chuang, 2006), possibly in concert with an
increased innate immune response.
Poly (ADP-ribose) polymerase catalyzes the attachment of ADP
ribose units from NAD to nuclear proteins after DNA damage,
resulting in three major outcomes, DNA repair, activation of tran-
scription factors (notably NF-κB), and/or cell death due to NAD
depletion and release of apoptosis releasing factor frommitochon-
dria (Kauppinen and Swanson, 2007). PARP negatively regulates
α-synuclein expression by binding to the α-synuclein promoter
Rep1 region (Chiba-Falek et al., 2005) and α-synuclein protein
suppresses PARP activity (Adamczyk and Kazmierczak, 2009).
Inhibition of PARP activation protects mice from MPTP-induced
parkinsonism (Mandir et al., 1999; Leng and Chuang, 2006).
PARP may protect against PD through increasing innate immune
signaling.
ATM is a kinase that is recruited to phosphorylate histones for
DNA repair, signaling molecules for cell cycle arrest or apopto-
sis, and nuclear IKKγ (NF-κB essential modulator; Habraken and
Piette, 2006; Hinz et al., 2010; Hadian and Krappmann, 2011).
Phosphorylation of IKKγ leads to its ubiquitination and cyto-
plasmic translocation where it associates with the rest of the
IKK complex, resulting in IKK activation followed by subsequent
NF-κB activation and inﬂammatory cytokines production (Chen,
2005). ATM has also recently been shown to regulate proteasome-
mediated protein turnover through suppression of the ISG15
pathway (Wood et al., 2011). ISG15 is an interferon-stimulated
gene activated by viral infection and important in antiviral defense
and innate immunity (Skaug andChen, 2010). It is a ubiquitin-like
protein that can be attached to both host and viral proteins (Skaug
and Chen, 2010). ATM-deﬁcient mice exhibit a selective loss of
dopamine nigrostriatal neurons (Eilam et al., 1998), implicating
dysfunctionof ubiquitination as a factor inPDneurodegeneration,
and speciﬁcally of ubiquitination in the innate immune system.
INNATE IMMUNITY AND UBIQUITINATION IN PD
The expression of ISG15 is increased in Crohn’s disease (Labbe
et al., 2011), an inﬂammatory bowel disorder sharing common
genetic and environmental risk factors with PD (Bihari and Lees,
1987; Bialecka et al., 2007). Both ISG15 and LRRK2 (PARK8)
are targets of interferon regulation (Figure 2). Interferon also
regulates proteasome processing of ubiquitinated protein degra-
dation into small peptides (Rivett et al., 2001; Piccinini et al., 2003;
Figure 2). Ubiquitin is a small molecule and through lysine 48 and
lysine 63 forms polyubiquitin chains for protein degradation and
cellular localization (Ikeda and Dikic, 2008).
Among PARK genes, parkin has a variety of functions. It not
only promotes lysine 48 linked ubiquitination for substrate degra-
dation via the proteasome,but also functions in lysine 63 ubiquitin
chain assembly to regulate diverse cellular processes, such as ribo-
some control, protein sorting and trafﬁcking, and endocytosis of
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FIGURE 2 | Innate immunity and the ubiquitin–proteasome system in
PD. Innate immunity is used by the cell to increase proteasome degradation
of unwanted proteins by direct and indirect stimulation of the protesome
through interferon-γ and ISG15, a ubiquitin-like protein that can be attached
to both host and viral proteins. ATM (and appropriately functioning LRRK2)
usually stimulates innate immune signaling when necessary. However,
ATM also regulates proteasome-mediated protein turnover through
suppression of the ISG15 pathway, and together with dysfunctional LRRK2
could decrease proteasome activity necessary for an adequate immune
response and the degradation of normal cellular protein substrates, like
dimer or tetramer forms of α-synuclein. As these forms are normally
degraded through the ubiquitin/proteasome and lysosome/autophagy
pathways, along with other cellular substrates, dysfunction in these
pathways would increase α-synuclein to form toxic oligomeric species that
also inhibit the proteasome and autophagy pathways, as well as innate
immunity. This scenario would lead to the increase in toxic oligomers of
α-synuclein that aggregate into ﬁbrils to form Lewy bodies over time.
membraneproteins (Doss-Pepe et al.,2005). Lysine 63 linkedubiq-
uitin chains promote the degradationofmembrane proteins by the
lysosome (Doss-Pepe et al., 2005). It is notable that α-synuclein is
degraded via both the proteasome and lysosome pathways (Shin
et al., 2005), suggestive that lysine 48 and lysine 63 linked ubiquitin
chains are both important in the pathogenesis of PD (Figure 2).
UCH-L1 has two opposing enzymatic activities, deubiquitination
and ubiquityl ligase. The UCH-L1 ligase activity forms lysine 63
linked polyubiquitin chains (Liu et al., 2002). Lysine 63multiubiq-
uitin chains are also stimulated by α-synuclein (Doss-Pepe et al.,
2005), and α-synuclein ﬁlaments and oligomers or its mutants
inhibit proteasome function (Tanaka et al., 2001; Lindersson et al.,
2004). These three genetically linked PD proteins all contribute
to lysine 63 multiubiquitin chain formation. Dysfunction of this
system is likely to decrease innate immune responses in PD.
Both lysine 48 and lysine 63 linked ubiquitin chains are known
to be involved in anti-pathogen signaling cascades. In particular,
lysine 63 linked ubiquitination is essential for NF-κB activation
(detailed in review of Wu et al., 2006). Phosphorylation of IκB
that releases NF-κB only occurs when the kinase IKKβ is released
from its complex following IKKγ phosphorylation and lysine 63
linked degradation. Some other key immune response signaling
molecules, such as TRAF6, also function as the lysine 63 linked
ubiquitin E3 ligase to activate kinase activity (Kawai and Akira,
2006), and TRAF5 has been identiﬁed as a downstream target of
VISA (see below) that mediates both IRF-3 and NF-κB activation
(Tang andWang, 2010).
INNATE IMMUNITY AND MITOCHONDRIAL FUNCTION IN PD
The proper functioning of mitochondria is crucial for adequate
innate immune defense (Qi et al., 2007; Tang and Wang, 2010;
West et al., 2011). Intracellular double-stranded RNA originat-
ing from viruses or virus replication is recognized by RIG-I
and Mda5, which contain a caspase recruitment domain (CARD;
Figure 3). Activated RIG-I/Mda5 passes the signal to mitochondr-
ial antiviral signaling (MAVS/VISA) proteins via a CARD–CARD
domain interaction (Figure 3). The C-terminal of MAVS/VISA
bind to mitochondria to activate NF-κB and start interferon α
and β production (Qi et al., 2007; Figure 3). Upon viral infection,
MAVS/VISA immigrate from the outer membrane into the mito-
chondrial detergent-resistant membrane fraction, suggesting that
mitochondria react and contribute to antiviral signaling (Qi et al.,
2007; Figure 3). In addition to regulating antiviral signaling, there
is mounting evidence that mitochondria facilitate antibacterial
immunity by generating reactive oxygen species and contributing
to innate immune activation following cellular damage and stress
(Nakahira et al., 2011).
Most nuclear encoded PARK gene products are located within
mitochondria (Table 1), such as PINK1, DJ-1, Omi/HtrA2, and
LRRK2, suggesting mitochondrial dysfunction is common in PD.
The mitochondrial complex I has been shown to be selectively
reduced in PD vulnerable regions, such as the substantia nigra
(Schapira et al., 1989). The mitochondrial complex I inhibitor
rotenone and mitochondrial toxin MPTP (1-methyl 4-phenyl
1,2,3,6-tetrahydropyridine) induce selective dopamine neuron
loss and a parkinsonian syndrome and have been used as a major
model for studying the tissue aspects of PD (Langston and Bal-
lard, 1984; Betarbet et al., 2000). These changes may decrease the
cellular responses of the innate immune system in PD.
INNATE IMMUNITY AND SYNAPTIC TRAFFICKING IN PD
Most enveloped animal RNA and DNA viruses enter host cells via
receptor-medicated endocytosis or viral membrane fusion with
the plasma membrane in order to replicate. Endocytosis impinges
on viral infection at a number of different cellular levels, from
the plasma membrane to endosome to lysosome or alternatively
to Golgi, and to ER (Figure 4; Hacker et al., 1998; Leadbetter
et al., 2002; Diebold et al., 2004). Viral proteins accumulate in
the ER during viral replication and elicit ER stress. Viral repli-
cation induced ER stress disturbs vesicle trafﬁcking within the
intracellular membranous web (Goodridge et al., 2011).
Many PARK genes are associated with endocytosis and synaptic
vesicle trafﬁcking. α-Synuclein, parkin and UCH-L1 concentrate
in the presynapse and associate with synaptic vesicles, anchor-
ing and regulating the undocked pool of presynaptic vesicles (Di
Rosa et al., 2003; Ferrer, 2009). α-Synuclein acts as a molecular
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FIGURE 3 | Innate immunity and mitochondria in PD. Many PARK related
gene products are located in mitochondria, implicating mitochondrial
dysfunction in PD. Interestingly, MAVS/VISA that are attached to the outer
membrane of mitochondria are involved in viral infection signaling by
activating TRAF6 andTRAF5. Phosphorylation of Iκβα and IRF-3 leads to
nuclear translocation of transcription factors and the production of cytokines.
Table 1 | Cellular localization and functions PARK and related genes
Cellular location indicative functions in mitochondria
and synaptic trafficking
Ubiquitination Reference
Parkin Outer mitochondrial membrane Synaptic vesicles and the
synaptic membrane
Lysine 48-, 63-linked ubiquitin E3 ligase Kubo et al. (2001); Darios et al. (2003)
DJ-1 Mitochondrial matrix and inter-membrane space NA Zhang et al., 2005)
PINK1 Mitochondria Upstream of parkin Valente et al. (2004)
Omi/HtrA2 Mitochondrial inter-membrane space NA Strauss et al. (2005)
LRRK2 Outer mitochondrial membrane NA West et al. (2005)
α-synuclein Presynaptic terminal Promote 63 linked ubiquitin assemble Iwai et al. (1995)
UCH-L1 Synaptic vesicle Lysine 63 linked ubiquitin E3 ligase Liu et al. (2002)
VISA Outer mitochondrial membrane NA Seth et al. (2005)
NA, not available.
www.frontiersin.org March 2012 | Volume 3 | Article 33 | 5
Huang and Halliday Innate immunity and Parkinson’s disease
late endosome
extracellular
intracellular
early
endosome
α-syn
A  Secretory/exocytosis pathway B Viral receptor mediated endocytosis pathway
t-SNARE
v-SNARE
virus
Golgi apparatus
Endoplasmic reticulum
Nucleus
FIGURE 4 | Synaptic trafficking failure and viral intake leading to
synaptic dysfunction in PD. Left: The endoplasmic reticulum is composed of
a membranous network of tubes and cisternae enclosed in a membrane. It is
continuous with the membrane surrounding the nuclear membrane and
connects with the Golgi network via the vesicles carrying newly synthesized
proteins. Certain vesicle-trafﬁcking steps are required for the translocation of
a vesicle from the Golgi apparatus to the plasma membrane. A transport
vesicle is tethered and docked at the target membrane to form a tight SNARE
complex, thus to merge the vesicle membrane with the target membrane and
evacuate neurotransmitters into the extracellular space. The vesicle releasing
process is under the assistance of α-synuclein, CDCrel-1, and synaptotagmin.
Right: Viruses enter host cells through endosomes. Late endosomes fuse
with or convert to lysosomes to degrade its contents, or alternatively it forms
budding vesicles that pass to the trans-Golgi region and translocate to the
Golgi and endoplasmic reticulum. The endoplasmic reticulum is coated with
ribosomes, which assemble the viral amino acids into viral proteins.
chaperone, assisting in the folding and refolding of synaptic
proteins called SNAREs, which are crucial for the release of neuro-
transmitters at the neuronal synapse, vesicle recycling, and synap-
tic integrity (Chandra et al., 2005). Upon the arrival of action
potentials at the synaptic terminal, SNARE complexes, assembly of
vesicle membrane (v-SNARE) and the presynaptic plasma mem-
brane (t-SNARE), fuse the vesicle at the plasma membrane to
release neurotransmitter into the synaptic cleft (Chandra et al.,
2005; Fortin et al., 2005). Parkin ubiquitinates and regulates the
turnover of the synaptic vesicle-associated protein, CDCrel-1, a
synaptic vesicle-enriched septin GTPase implicated in the inhibi-
tion of exocytosis through its interactions with the SNARE com-
plex component, syntaxin (Zhang et al., 2000). Another substrate
of parkin is synaptotagmin XI, a member of the synaptotagmin
family that is well characterized in vesicle formation and docking
by interaction with SNAREs (Huynh et al., 2003). Loss of func-
tion of α-synuclein, parkin, or DJ-1 reduces neurotransmission
and synaptic vesicle trafﬁcking (Abeliovich et al., 2000; Goldberg
et al., 2005). UCH-L1 deﬁcient mice also show altered vesicle
transport gene expression (Bonin et al., 2004). Reduced innate
immunity allowing for pathogen replication would signiﬁcantly
exacerbate any loss of synaptic function caused by PARK gene
products (Figure 4) precipitating frank degeneration.
CONCLUSION
A number of intrinsically driven cellular pathways shown to be
dysfunctional in PD are important in mediating innate immune
signaling. These important intracellular pathways have been iden-
tiﬁed through genetic studies in patients with PD. More recent
genetic studies have also implicated immune pathways in the
pathogenesis of PD. In particular, we have identiﬁed a number
of PARK gene products as well as other enzymes that have dual
roles in innate immune signaling as well as proteasome, lyso-
some, and mitochondrial functioning. The additional enzymes
identiﬁed are important for DNA repair and regulation, ubiqui-
tination, mitochondrial function, and synaptic trafﬁcking. These
pathways appear to lose their ability to mount an adequate innate
immune response to PD and experimental manipulation of many
of these intracellular molecules has been associated with charac-
teristic PD pathologies in animal models. Intriguing new data also
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suggest that peripheral immune responses may be involved, with
the potential to alleviate such peripheral dysfunctionmore directly
in patients with PD.
Most important, the molecular pathways involved are likely
to function in a cell type speciﬁc manner (Ledesma et al.,
2002), a concept that has not yet been evaluated substantially
in patients with PD. The cross-talk between neurons and glia
is crucial for an adequate immune response, with astrocytes
considered particularly important (Halliday and Stevens, 2011;
Schmidt et al., 2011). Astrocytic endfeet form part of the BBB
and may serve as ideal sentinel cells able to sense the appear-
ance of toxins and viral pathogens (Scumpia et al., 2005), similar
to their cousins found in the gut (Savidge et al., 2007; Dane-
man and Rescigno, 2009). Astroglia in both the brain and gut
regulate barrier function and membrane permeability (Savidge
et al., 2007; Daneman and Rescigno, 2009), functions which
may be important for the cell to cell transfer of α-synuclein
pathology as well as more traditional infectious agents. The
increased expression of PARK gene proteins in astrocytes (see
above) and their lack of activation to PD pathology in patients
(Mirza et al., 2000; Halliday and Stevens, 2011) lends weight to
a loss of innate immunity and BBB function in PD that poten-
tially increases membrane and cellular permeability leading to
increased toxin and pathogen inﬁltration in the brain. In addition
to the direct cellular damage to vulnerable neurons this would ini-
tiate, pathogen exposure may also activate the alternate adaptive
immune responses that are thought to participate in propagating
the pathology of PD.
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